Dapagliflozin for patients with heart failure and reduced ejection fraction

被引：1
|
作者：
Ferry, Abigail [1 ]
机构：
[1] Allegheny Gen Hosp, Div Adv Heart Failure & Cardiac Transplant, Pittsburgh, PA 15212 USA
来源：
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2022年 / 35卷 / 09期
关键词：
dapagliflozin; heart failure; SGLT2; reduced ejection fraction; type; 2; diabetes; cardiovascular;
D O I：
10.1097/01.JAA.0000840504.15807.70
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The CDC estimates that national costs related to heart failure exceed $30 billion annually. Clinicians and researchers continue to aggressively pursue measures aimed at reducing morbidity and mortality among the 6.5 million adults affected by the disease. Dapagliflozin recently emerged as a promising FDA-approved therapy for patients with systolic heart failure, more commonly referred to as heart failure with reduced ejection fraction.
引用
下载
收藏
页码：51 / 53
页数：3
相关论文
共 50 条
  • [1] Dapagliflozin in patients with heart failure and reduced ejection fraction
    Giorgio Colombo
    Rosa Casella
    Alessia Cazzaniga
    Chiara Casiraghi
    Internal and Emergency Medicine, 2020, 15 : 515 - 517
  • [2] Dapagliflozin in patients with heart failure and reduced ejection fraction
    Colombo, Giorgio
    Casella, Rosa
    Cazzaniga, Alessia
    Casiraghi, Chiara
    INTERNAL AND EMERGENCY MEDICINE, 2020, 15 (03) : 515 - 517
  • [3] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
    McMurray, J. J. V.
    Solomon, S. D.
    Inzucchi, S. E.
    Kober, L.
    Kosiborod, M. N.
    Martinez, F. A.
    Ponikowski, P.
    Sabatine, M. S.
    Anand, I. S.
    Belohlavek, J.
    Bohm, M.
    Chiang, C. -E.
    Chopra, V. K.
    de Boer, R. A.
    Desai, A. S.
    Diez, M.
    Drozdz, J.
    Dukat, A.
    Ge, J.
    Howlett, J. G.
    Katova, T.
    Kitakaze, M.
    Ljungman, C. E. A.
    Merkely, B.
    Nicolau, J. C.
    O'Meara, E.
    Petrie, M. C.
    Vinh, P. N.
    Schou, M.
    Tereshchenko, S.
    Verma, S.
    Held, C.
    DeMets, D. L.
    Docherty, K. F.
    Jhund, P. S.
    Bengtsson, O.
    Sjostrand, M.
    Langkilde, A. -M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 1995 - 2008
  • [4] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
    Borghi, Claudio
    Cicero, Arrigo F. G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (10): : 972 - 972
  • [5] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction REPLY
    McMurray, John J. V.
    Docherty, Kieran F.
    Jhund, Pardeep S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (10): : 973 - 973
  • [6] Multiparametric evaluation of the effects of dapagliflozin in patients with heart failure and reduced ejection fraction
    Marazia, S. Stefania
    Chiarello, G.
    Leonardo, A.
    Donateo, M.
    Di Mauro, M.
    Colonna, G.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 65 - 65
  • [7] THE INFLUENCE OF DAPAGLIFLOZIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
    Abu Much, Arsalan
    Hamzi, Salah
    Fardman, Alexander
    Massalha, Eias
    Freimark, Dov
    Shechter, Michael
    Grupper, Avishay
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 496 - 496
  • [8] Effect of dapagliflozin on ventricular repolarization in patients with heart failure with reduced ejection fraction
    Nakase, Masaaki
    Yahagi, Kazuyuki
    Horiuchi, Yu
    Asami, Masahiko
    Yuzawa, Hitomi
    Komiyama, Kota
    Tanaka, Jun
    Aoki, Jiro
    Tanabe, Kengo
    HEART AND VESSELS, 2023, 38 (12) : 1414 - 1421
  • [9] Effect of dapagliflozin on ventricular repolarization in patients with heart failure with reduced ejection fraction
    Masaaki Nakase
    Kazuyuki Yahagi
    Yu Horiuchi
    Masahiko Asami
    Hitomi Yuzawa
    Kota Komiyama
    Jun Tanaka
    Jiro Aoki
    Kengo Tanabe
    Heart and Vessels, 2023, 38 : 1414 - 1421
  • [10] Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
    Solomon, S. D.
    McMurray, J. J., V
    Claggett, B.
    de Boer, R. A.
    DeMets, D.
    Hernandez, A. F.
    Inzucchi, S. E.
    Kosiborod, M. N.
    Lam, C. S. P.
    Martinez, F.
    Shah, S. J.
    Desai, A. S.
    Jhund, P. S.
    Belohlavek, J.
    Chiang, C-E
    Borleffs, C. J. W.
    Comin-Colet, J.
    Dobreanu, D.
    Drozdz, J.
    Fang, J. C.
    Alcocer-Gamba, M. A.
    Al Habeeb, W.
    Han, Y.
    Cabrera Honorio, J. W.
    Janssens, S. P.
    Katova, T.
    Kitakaze, M.
    Merkely, B.
    O'Meara, E.
    Saraiva, J. F. K.
    Tereshchenko, S. N.
    Thierer, J.
    Vaduganathan, M.
    Vardeny, O.
    Verma, S.
    Pham, V. N.
    Wilderang, U.
    Zaozerska, N.
    Bachus, E.
    Lindholm, D.
    Petersson, M.
    Langkilde, A. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, : 1089 - 1098
12345